Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients
Abstract The composition of the gut microbiome of patients with advanced non-small cell lung cancer is currently considered a factor influencing the effectiveness of treatment with immune checkpoint inhibitors. We aimed to evaluate the baseline gut microbiome composition in patients before receiving...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-89406-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850040028175007744 |
|---|---|
| author | Anna Grenda Ewelina Iwan Barbara Kuźnar-Kamińska Arkadiusz Bomba Katarzyna Bielińska Paweł Krawczyk Izabela Chmielewska Małgorzata Frąk Michał Szczyrek Anna Rolska-Kopińska Tomasz Jankowski Robert Kieszko Janusz Milanowski |
| author_facet | Anna Grenda Ewelina Iwan Barbara Kuźnar-Kamińska Arkadiusz Bomba Katarzyna Bielińska Paweł Krawczyk Izabela Chmielewska Małgorzata Frąk Michał Szczyrek Anna Rolska-Kopińska Tomasz Jankowski Robert Kieszko Janusz Milanowski |
| author_sort | Anna Grenda |
| collection | DOAJ |
| description | Abstract The composition of the gut microbiome of patients with advanced non-small cell lung cancer is currently considered a factor influencing the effectiveness of treatment with immune checkpoint inhibitors. We aimed to evaluate the baseline gut microbiome composition in patients before receiving first-line immunotherapy alone or combined with chemoimmunotherapy. We performed 16S rRNA sequencing based on hypervariable regions. Stool samples were collected from 52 patients with advanced NSCLC treated with immunotherapy or chemoimmunotherapy before treatment. We found that the Ruminococcaceae family, species Alistipes sp. genus Eubacterium ventriosum group and genus Marvinbryantia may be intestinal, microbiological predictors of response to treatment. Genus Akkermansia and species from the [Clostridum] leptum group predicted the length of PFS (progression-free survival). Longer OS (overall survival) is associated with bacteria from the Ruminococcaceae family genera [ Eubacterium ] ventriosum group, Marvinbryantia, Colidextribacter and species [Clostridum] leptum. Bacteria that have an adverse effect (shortening of PFS or OS) on the response to treatment using immune checkpoint inhibitors are Rothia genus, Streptococus salivarius, Streptococus, Family XIII AD3011 group and Family XIII AD3011 group, s. uncultured bacterium. The composition of intestinal flora can be a predictive factor for immunotherapy in NSCLC patients. Specific bacteria can be positively or negatively associated with response to treatment, progression-free survival, and overall survival. They can be potentially used as predictive markers in NSCLC patients treated with immunotherapy. |
| format | Article |
| id | doaj-art-e413ea36906c4dc097d27cdd8b063493 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-e413ea36906c4dc097d27cdd8b0634932025-08-20T02:56:11ZengNature PortfolioScientific Reports2045-23222025-02-0115111210.1038/s41598-025-89406-1Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patientsAnna Grenda0Ewelina Iwan1Barbara Kuźnar-Kamińska2Arkadiusz Bomba3Katarzyna Bielińska4Paweł Krawczyk5Izabela Chmielewska6Małgorzata Frąk7Michał Szczyrek8Anna Rolska-Kopińska9Tomasz Jankowski10Robert Kieszko11Janusz Milanowski12Department of Pneumonology, Oncology and Allergology, Medical University of LublinDepartment of Omics Analyses, National Veterinary Research InstituteDepartment of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical SciencesDepartment of Omics Analyses, National Veterinary Research InstituteDepartment of Omics Analyses, National Veterinary Research InstituteDepartment of Pneumonology, Oncology and Allergology, Medical University of LublinDepartment of Pneumonology, Oncology and Allergology, Medical University of LublinDepartment of Pneumonology, Oncology and Allergology, Medical University of LublinDepartment of Pneumonology, Oncology and Allergology, Medical University of LublinDepartment of Pneumonology, Oncology and Allergology, Medical University of LublinDepartment of Pneumonology, Oncology and Allergology, Medical University of LublinDepartment of Pneumonology, Oncology and Allergology, Medical University of LublinDepartment of Pneumonology, Oncology and Allergology, Medical University of LublinAbstract The composition of the gut microbiome of patients with advanced non-small cell lung cancer is currently considered a factor influencing the effectiveness of treatment with immune checkpoint inhibitors. We aimed to evaluate the baseline gut microbiome composition in patients before receiving first-line immunotherapy alone or combined with chemoimmunotherapy. We performed 16S rRNA sequencing based on hypervariable regions. Stool samples were collected from 52 patients with advanced NSCLC treated with immunotherapy or chemoimmunotherapy before treatment. We found that the Ruminococcaceae family, species Alistipes sp. genus Eubacterium ventriosum group and genus Marvinbryantia may be intestinal, microbiological predictors of response to treatment. Genus Akkermansia and species from the [Clostridum] leptum group predicted the length of PFS (progression-free survival). Longer OS (overall survival) is associated with bacteria from the Ruminococcaceae family genera [ Eubacterium ] ventriosum group, Marvinbryantia, Colidextribacter and species [Clostridum] leptum. Bacteria that have an adverse effect (shortening of PFS or OS) on the response to treatment using immune checkpoint inhibitors are Rothia genus, Streptococus salivarius, Streptococus, Family XIII AD3011 group and Family XIII AD3011 group, s. uncultured bacterium. The composition of intestinal flora can be a predictive factor for immunotherapy in NSCLC patients. Specific bacteria can be positively or negatively associated with response to treatment, progression-free survival, and overall survival. They can be potentially used as predictive markers in NSCLC patients treated with immunotherapy.https://doi.org/10.1038/s41598-025-89406-1MicrobiomeNSCLCImmunotherapy16S rRNAImmunotherapy efficacy |
| spellingShingle | Anna Grenda Ewelina Iwan Barbara Kuźnar-Kamińska Arkadiusz Bomba Katarzyna Bielińska Paweł Krawczyk Izabela Chmielewska Małgorzata Frąk Michał Szczyrek Anna Rolska-Kopińska Tomasz Jankowski Robert Kieszko Janusz Milanowski Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients Scientific Reports Microbiome NSCLC Immunotherapy 16S rRNA Immunotherapy efficacy |
| title | Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients |
| title_full | Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients |
| title_fullStr | Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients |
| title_full_unstemmed | Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients |
| title_short | Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients |
| title_sort | gut microbial predictors of first line immunotherapy efficacy in advanced nsclc patients |
| topic | Microbiome NSCLC Immunotherapy 16S rRNA Immunotherapy efficacy |
| url | https://doi.org/10.1038/s41598-025-89406-1 |
| work_keys_str_mv | AT annagrenda gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT ewelinaiwan gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT barbarakuznarkaminska gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT arkadiuszbomba gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT katarzynabielinska gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT pawełkrawczyk gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT izabelachmielewska gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT małgorzatafrak gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT michałszczyrek gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT annarolskakopinska gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT tomaszjankowski gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT robertkieszko gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients AT januszmilanowski gutmicrobialpredictorsoffirstlineimmunotherapyefficacyinadvancednsclcpatients |